16:15 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

J&J planning submission for Invokana in CKD following Phase III readout

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) said Invokana canagliflozin met the primary endpoint in the Phase III CREDENCE trial to treat chronic kidney disease in patients with Type II diabetes. A...
22:10 , Jul 16, 2018 |  BC Extra  |  Clinical News

J&J planning submission for Invokana in CKD

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) said Invokana canagliflozin met the primary endpoint in the Phase III CREDENCE trial to treat chronic kidney disease in patients with Type II diabetes. A...
23:35 , Jan 31, 2018 |  BC Extra  |  Company News

Lilly falls on diabetes and animal health concerns

Despite 4Q17 figures that outperformed analyst expectations, Eli Lilly and Co. (NYSE:LLY) fell $4.64 to $81.45 on Wednesday after the pharma said it continues to see pricing pressure on its diabetes products. Lilly also reported...
21:44 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

Janssen submits sNDA for Invokana

Johnson & Johnson (NYSE:JNJ) submitted an sNDA to FDA for Invokana canagliflozin (JNJ-28431754, TA-7284) to reduce the risk of major adverse cardiovascular events (MACE) in adult Type II diabetes patients at risk for or with...
19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race is...
23:47 , Aug 17, 2017 |  BC Week In Review  |  Clinical News

Japan approves Mitsubishi's Canalia for Type II diabetes

Last month, Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) and Daiichi Sankyo Co. Ltd. (Tokyo:4568) said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Canalia teneligliptin/canagliflozin (MT-2412) to treat Type II diabetes. Canalia is an oral fixed-dose...
19:49 , Aug 4, 2017 |  BC Week In Review  |  Company News

CVS unveils changes to 2018 formulary

CVS Health Corp. (NYSE:CVS) will remove Gaucher's disease drug Elelyso taliglucerase alfa and diabetes drug Jardiance empagliflozin from its 2018 Standard Control Formulary. Elelyso from Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX) is...
00:22 , Aug 3, 2017 |  BC Extra  |  Politics & Policy

CVS unveils changes to 2018 formulary

CVS Health Corp. (NYSE:CVS) will remove Gaucher's disease drug Elelyso taliglucerase alfa and diabetes drug Jardiance empagliflozin from its 2018 Standard Control Formulary. Elelyso from Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX)...
21:31 , Jun 16, 2017 |  BC Week In Review  |  Clinical News

J&J's Invokana improves CV outcomes despite amputation risk

Johnson & Johnson (NYSE:JNJ) reported pooled data from the double-blind, international Phase III CANVAS and Phase IV CANVAS-R trials in a total of 10,142 Type II diabetics at high cardiovascular (CV) risk showing that Invokana...
20:03 , Jun 13, 2017 |  BC Extra  |  Clinical News

Invokana improves CV outcomes, despite amputation risk

Pooled data from two studies showed that compared with placebo, Invokana canagliflozin from Johnson & Johnson (NYSE:JNJ) reduced the risk of cardiovascular events in higher-risk patients with Type II diabetes, but led to a higher...